WntResearch files a patent application for the treatment of Acute Myeloid Leukemia

WntResearch announces today that the company has filed a new patent application that broadly covers the use of Foxy-5 in the treatment of Acute Myeloid Leukemia (AML).

In a research exchange with a Brazilian research group at the Hematology and Transfusion Medicine Center at University of Campinas/Hemocentro-UNICAMP in São Paulo, WNT Research has provided  Foxy-5 and expertise of its use in the experimental studies. In exchange the company has  secured that all intellectual property rights accrue WNTResearch based on the research group’s research with Foxy-5 on AML cells.

The research group has concluded that Foxy-5, by restoring WNT5a levels, could represent a strategy to counterbalance several oncogenic processes present in leukemia by inhibiting cell growth. Thus, Foxy-5 treatment may be an important approach to impair AML growth and maintenance and arises as a promising therapeutic target.

Read the full Abstract presented on American Society of Hematology Publications: https://ashpublications.org/blood/article/138/Supplement%201/2949/478942  

Relapse is still a common scenario in the treatment of acute myeloid leukemia. It occurs in 40–50% of younger patients and in the vast majority of elderly. The global AML market is currently expected to grow sharply from $ 1.4 billion in 2019 to $ 5.1 billion in 2029.

“WntResearch is continuously studying the properties of Foxy-5 in the treatment of various types of cancer. We have now successfully identified new properties of Foxy-5 that indicate that the drug candidate could be used in the treatment of acute myeloid leukemia. The results on which our new patent application is based are important for the strategy to continue to develop and evaluate the clinical application of Foxy-5. We will continue to study Foxy-5 for treatment of AML and we are now evaluating potential research collaborations with internationally recognized research groups, ” says WntResearch's CEO, Anders Rabbe.

For further information:

Anders Rabbe, acting CEO
Phone: +46 707 646 500
E-mail: anders.rabbe@wntresearch.com

This information was submitted for publication, through the agency of the contact person set out above, on December 13, 2021.

About WntResearch

WntResearch is a biotech company in oncology that develops new therapies intended to prevent the metastatic process. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumor cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 percent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer.

WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com